Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H11NO4 |
Molecular Weight | 209.1986 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C=CC(=C1)C(O)=O)[C@H](N)C(O)=O
InChI
InChIKey=SGIKDIUCJAUSRD-QMMMGPOBSA-N
InChI=1S/C10H11NO4/c1-5-4-6(9(12)13)2-3-7(5)8(11)10(14)15/h2-4,8H,11H2,1H3,(H,12,13)(H,14,15)/t8-/m0/s1
Molecular Formula | C10H11NO4 |
Molecular Weight | 209.1986 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Sources: http://adisinsight.springer.com/drugs/800011092
Curator's Comment: # Lilly Research Laboratories, Eli Lilly and Company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q13255|||Q9NU10 Gene ID: 2911.0 Gene Symbol: GRM1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10218860 |
8.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine. | 1993 Jan 15 |
|
Reduction of sensory and metabotropic glutamate receptor responses in the thalamus by the novel metabotropic glutamate receptor-1-selective antagonist S-2-methyl-4-carboxy-phenylglycine. | 1998 Aug |
|
Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. | 1999 Feb |
|
Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). | 1999 Feb 26 |
|
mGluR1 antagonist decreases tyrosine phosphorylation of NMDA receptor and attenuates infarct size after transient focal cerebral ischemia. | 2008 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18248625
in rats: administration of LY367385 (10 mg/kg) reduced the infarct volume at 24 h after the start of reperfusion.
Route of Administration:
Intraperitoneal
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:01:30 GMT 2023
by
admin
on
Sat Dec 16 10:01:30 GMT 2023
|
Record UNII |
D8UW47H17B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5311261
Created by
admin on Sat Dec 16 10:01:30 GMT 2023 , Edited by admin on Sat Dec 16 10:01:30 GMT 2023
|
PRIMARY | |||
|
D8UW47H17B
Created by
admin on Sat Dec 16 10:01:30 GMT 2023 , Edited by admin on Sat Dec 16 10:01:30 GMT 2023
|
PRIMARY | |||
|
198419-91-9
Created by
admin on Sat Dec 16 10:01:30 GMT 2023 , Edited by admin on Sat Dec 16 10:01:30 GMT 2023
|
PRIMARY | |||
|
DTXSID2042563
Created by
admin on Sat Dec 16 10:01:30 GMT 2023 , Edited by admin on Sat Dec 16 10:01:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |